

Drug development in Alzheimer's disease: the path to

Alzheimer's Research and Therapy
8, 39

DOI: 10.1186/s13195-016-0207-9

Citation Report

#	ARTICLE	IF	CITATIONS
1	La prevención de las demencias, un reto inmediato. Revista Clinica Espanola, 2016, 216, 483-484.	0.6	0
2	Alzheimer's disease: the role of mitochondrial dysfunction and potential new therapies. Bioscience Horizons, 2016, 9, .	0.6	15
3	Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 57, 1105-1121.	2.6	1,123
4	Otophyllaside B Protects Against A β Toxicity in Caenorhabditis elegans Models of Alzheimer's Disease. Natural Products and Bioprospecting, 2017, 7, 207-214.	4.3	29
5	Comparative study of therapeutic antibody candidates derived from mini-library and clonal cell lines. Biotechnology Progress, 2017, 33, 1456-1462.	2.6	26
6	Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery. Neuroscience and Biobehavioral Reviews, 2017, 76, 4-21.	6.1	41
7	Mechanisms of vascular disease in dementia: what does industry want to know?. Clinical Science, 2017, 131, 799-802.	4.3	4
8	Alzheimer's Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health. Journal of Alzheimer's Disease, 2017, 58, 979-992.	2.6	70
9	Alzheimer's disease drug development pipeline: 2017. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 367-384.	3.7	331
10	Targeting Free Radicals in Oxidative Stress-Related Human Diseases. Trends in Pharmacological Sciences, 2017, 38, 592-607.	8.7	781
11	RNA-binding proteins with prion-like domains in health and disease. Biochemical Journal, 2017, 474, 1417-1438.	3.7	347
13	Research advances in the treatment of Alzheimer's disease with polysaccharides from traditional Chinese medicine. Chinese Journal of Natural Medicines, 2017, 15, 641-652.	1.3	13
14	Comments on the "enexus" meeting report regarding dementia and cancer. Alzheimer's and Dementia, 2017, 13, 720-721.	0.8	1
15	A modified formulation of Huanglian-Jie-Du-Tang reduces memory impairments and A β -amyloid plaques in a triple transgenic mouse model of Alzheimer's disease. Scientific Reports, 2017, 7, 6238.	3.3	35
16	Anti-Alzheimer's potential of berberine using surface decorated multi-walled carbon nanotubes: A preclinical evidence. International Journal of Pharmaceutics, 2017, 530, 263-278.	5.2	81
17	Prevention of Alzheimer's Disease: Lessons Learned and Applied. Journal of the American Geriatrics Society, 2017, 65, 2128-2133.	2.6	67
18	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. Journal of Alzheimer's Disease, 2017, 61, 169-183.	2.6	21
19	A peptide-based near-infrared fluorescence probe for dynamic monitoring senile plaques in Alzheimer's disease mouse model. Science Bulletin, 2017, 62, 1593-1601.	9.0	10

#	ARTICLE	IF	CITATIONS
20	Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 491-505.	2.6	57
21	Rebalancing β -Amyloid-Induced Decrease of ATP Level by Amorphous Nano/Micro Polyphosphate: Suppression of the Neurotoxic Effect of Amyloid β -Protein Fragment 25-35. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2154.	4.1	26
22	Computer-Aided Drug Design Applied to Marine Drug Discovery: Meridianins as Alzheimer's Disease Therapeutic Agents. <i>Marine Drugs</i> , 2017, 15, 366.	4.6	42
23	β -Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View. <i>Molecules</i> , 2017, 22, 1692.	3.8	82
24	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60.	6.2	316
25	Advances in Drug Discovery and Development in Geriatric Psychiatry. <i>Current Psychiatry Reports</i> , 2018, 20, 10.	4.5	5
26	A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 900-906.	2.7	83
27	Commentary on Apathy as a Model for Investigating Behavioral and Psychological Symptoms in Dementia. <i>Journal of the American Geriatrics Society</i> , 2018, 66, S13-S16.	2.6	6
29	Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1195-1214.	3.5	44
30	Preparation of Tetradentate Copper Chelators as Potential Anti-Alzheimer Agents. <i>ChemMedChem</i> , 2018, 13, 684-704.	3.2	38
31	Supratherapeutic concentrations of cilostazol inhibits β -amyloid oligomerization in vitro. <i>Neuroscience Letters</i> , 2018, 677, 19-25.	2.1	12
32	Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. <i>AAPS Journal</i> , 2018, 20, 46.	4.4	46
33	Big Data in Drug Discovery. <i>Progress in Medicinal Chemistry</i> , 2018, 57, 277-356.	10.4	36
34	Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S405-S426.	2.6	66
35	Young Blood Plasma Administration to Fight Alzheimer's Disease?. <i>Rejuvenation Research</i> , 2018, 21, 178-181.	1.8	8
36	Calcium signaling and molecular mechanisms underlying neurodegenerative diseases. <i>Cell Calcium</i> , 2018, 70, 87-94.	2.4	248
37	Alzheimer's Disease Therapy: Present and Future Molecules. <i>Neuromethods</i> , 2018, , 3-22.	0.3	4
38	A reagent-free paper-based sensor embedded in a 3D printing device for cholinesterase activity measurement in serum. <i>Sensors and Actuators B: Chemical</i> , 2018, 258, 1015-1021.	7.8	67

#	ARTICLE	IF	CITATIONS
39	Amylin in Alzheimer's disease: Pathological peptide or potential treatment?. Neuropharmacology, 2018, 136, 287-297.	4.1	23
40	Novel recruitment models will drive Alzheimer's trial success. Alzheimer's and Dementia, 2018, 14, 117-119.	0.8	18
41	DEVELOPMENT OF AZELIRAGON, AN ORAL SMALL MOLECULE ANTAGONIST OF THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS, FOR THE POTENTIAL SLOWING OF LOSS OF COGNITION IN MILD ALZHEIMER'S DISEASE. Journal of prevention of Alzheimer's disease, The, 2018, 5, 1-6.	2.7	67
42	Therapeutic effect of Rho kinase inhibitor FSD-10 in a mouse model of Alzheimer's disease. Experimental and Therapeutic Medicine, 2018, 16, 3929-3938.	1.8	10
43	Diagnostic Validation for Participants in the Washington State Parkinson Disease Registry. Parkinson's Disease, 2018, 2018, 1-6.	1.1	17
44	Preparation of 4-Flexible Amino-2-Arylethenyl-Quinoline Derivatives as Multi-target Agents for the Treatment of Alzheimer's Disease. Molecules, 2018, 23, 3100.	3.8	12
45	Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model. Cell Cycle, 2018, 17, 2321-2334.	2.6	7
46	Study partners: essential collaborators in discovering treatments for Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 101.	6.2	29
47	Alzheimer's disease (AD) therapeutics 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochemical Pharmacology, 2018, 158, 359-375.	4.4	59
48	Alzheimer's disease (AD) therapeutics 2: Beyond amyloid Re-defining AD and its causality to discover effective therapeutics. Biochemical Pharmacology, 2018, 158, 376-401.	4.4	24
49	Human neural stem cell transplantation improves cognition in a murine model of Alzheimer's disease. Scientific Reports, 2018, 8, 14776.	3.3	81
50	Re-thinking Alzheimer's disease therapeutic targets using gene-based tests. EBioMedicine, 2018, 37, 461-470.	6.1	28
51	Medicines management issues in dementia and coping strategies used by people living with dementia and family carers: A systematic review. International Journal of Geriatric Psychiatry, 2018, 33, 1562-1581.	2.7	42
52	Inflammation as a central mechanism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 575-590.	3.7	1,254
53	Cognitive composite score association with Alzheimer's disease plaque and tangle pathology. Alzheimer's Research and Therapy, 2018, 10, 90.	6.2	23
54	Natural Scaffolds with Multi-Target Activity for the Potential Treatment of Alzheimer's Disease. Molecules, 2018, 23, 2182.	3.8	27
55	Alzheimer: A Decade of Drug Design. Why Molecular Topology can be an Extra Edge?. Current Neuropharmacology, 2018, 16, 849-864.	2.9	7
56	Nuclear factor- κ B: Glucocorticoid-induced leucine zipper interface analogs suppress pathology in an Alzheimer's disease model. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 488-498.	3.7	8

#	ARTICLE	IF	CITATIONS
57	Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer's disease-related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence. <i>Neurobiology of Aging</i> , 2018, 70, 203-216.	3.1	55
58	Small molecule biomarkers in Alzheimer's disease. <i>OCL - Oilseeds and Fats, Crops and Lipids</i> , 2018, 25, D404.	1.4	5
59	Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7 and NMDA Receptor Antagonists. <i>Molecules</i> , 2018, 23, 230.	3.8	20
60	Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 350-356.	3.7	11
61	β -Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling. <i>Frontiers in Pharmacology</i> , 2018, 8, 969.	3.5	15
62	Ethnopharmacological Approaches for Dementia Therapy and Significance of Natural Products and Herbal Drugs. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 3.	3.4	93
63	The Quest for an Alzheimer Therapy. <i>Frontiers in Neurology</i> , 2018, 9, 108.	2.4	19
64	Advancing personalized treatment of Alzheimer's disease: a call for the N-of-1 trial design. <i>Future Neurology</i> , 2018, 13, 151-160.	0.5	9
65	Multicrossover Randomized Controlled Trial Designs in Alzheimer Disease. <i>Annals of Neurology</i> , 2018, 84, 168-175.	5.3	11
66	Sirtuin 1 and Alzheimer's disease: An up-to-date review. <i>Neuropeptides</i> , 2018, 71, 54-60.	2.2	65
67	The emerging roles of protein homeostasis-governing pathways in Alzheimer's disease. <i>Aging Cell</i> , 2018, 17, e12801.	6.7	88
68	Fractal regulation and incident Alzheimer's disease in elderly individuals. <i>Alzheimer's and Dementia</i> , 2018, 14, 1114-1125.	0.8	36
69	Alzheimer's disease hypothesis and related therapies. <i>Translational Neurodegeneration</i> , 2018, 7, 2.	8.0	385
70	MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 18.	6.2	21
71	Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform. <i>Neurochemistry International</i> , 2018, 120, 99-111.	3.8	26
72	Estudios farmacogenéticos en la enfermedad de Alzheimer. <i>Neurología</i> , 2022, 37, 287-303.	0.7	5
73	Diagnosis of Alzheimer's disease with Electroencephalography in a differential framework. <i>PLoS ONE</i> , 2018, 13, e0193607.	2.5	85
74	Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 615-628.	3.4	18

#	ARTICLE	IF	CITATIONS
75	Advanced Chemometric Modeling Approaches for the Design of Multitarget Drugs Against Neurodegenerative Diseases. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 155-186.	0.2	3
76	Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 290-303.	1.6	25
77	Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model. <i>Journal of Neuroinflammation</i> , 2019, 16, 166.	7.2	27
78	The Pathology of Rapid Cognitive Decline in Clinically Diagnosed Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 983-993.	2.6	12
79	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	9.0	182
80	Human glutamyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease. <i>Pharmacological Research</i> , 2019, 147, 104342.	7.1	21
81	Tackling gaps in developing life-changing treatments for dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 241-253.	3.7	17
82	Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNI2 cohorts. <i>Scientific Data</i> , 2019, 6, 212.	5.3	15
83	A Human Embryonic Stem Cell Model of $\text{A}\beta$ -Dependent Chronic Progressive Neurodegeneration. <i>Frontiers in Neuroscience</i> , 2019, 13, 1007.	2.8	6
84	Drugs for Targeted Therapies of Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2019, 26, 335-359.	2.4	12
85	Assessment of Fractal Characteristics of Locomotor Activity of Geriatric In-Patients With Alzheimer's Dementia. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 272.	3.4	7
86	Dietary Neuroketotherapeutics for Alzheimer's Disease: An Evidence Update and the Potential Role for Diet Quality. <i>Nutrients</i> , 2019, 11, 1910.	4.1	37
87	Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy. <i>Nature Communications</i> , 2019, 10, 3780.	12.8	132
88	Machine learning for comprehensive forecasting of Alzheimer's Disease progression. <i>Scientific Reports</i> , 2019, 9, 13622.	3.3	116
89	Plasmon-Activated Water Reduces Amyloid Burden and Improves Memory in Animals with Alzheimer's Disease. <i>Scientific Reports</i> , 2019, 9, 13252.	3.3	15
90	Face-to-Face and Digital Multidomain Lifestyle Interventions to Enhance Cognitive Reserve and Reduce Risk of Alzheimer's Disease and Related Dementias: A Review of Completed and Prospective Studies. <i>Nutrients</i> , 2019, 11, 2258.	4.1	35
91	CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer's disease. <i>PLoS ONE</i> , 2019, 14, e0222757.	2.5	4
92	Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 564.	3.3	15

#	ARTICLE	IF	CITATIONS
93	Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development. <i>Frontiers in Neuroscience</i> , 2018, 12, 1017.	2.8	65
94	Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities. <i>British Journal of Pharmacology</i> , 2019, 176, 3489-3507.	5.4	279
95	Link between the unfolded protein response and dysregulation of mitochondrial bioenergetics in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1419-1431.	5.4	37
97	Pharmacological Potential of Cilostazol for Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 559.	3.5	20
98	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	7.6	873
99	New Multitarget Hybrids Bearing Tacrine and Phenylbenzothiazole Motifs as Potential Drug Candidates for Alzheimer's Disease. <i>Molecules</i> , 2019, 24, 587.	3.8	20
100	Extracellular Vesicles from Mesenchymal Stem Cells Exert Pleiotropic Effects on Amyloid β , Inflammation, and Regeneration: A Spark of Hope for Alzheimer's Disease from Tiny Structures?. <i>BioEssays</i> , 2019, 41, e1800199.	2.5	29
101	Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APP ^{swe} /PS1 ^{dE9} Alzheimer's disease mice model. <i>Journal of Controlled Release</i> , 2019, 301, 62-75.	9.9	207
102	Heterogeneous drug tissue binding in brain regions of rats, Alzheimer's patients and controls: impact on translational drug development. <i>Scientific Reports</i> , 2019, 9, 5308.	3.3	15
103	The Role of Vitamin E in Aging and Alzheimer's Disease. , 2019, , 325-344.		1
104	The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics. <i>Current Opinion in Pharmacology</i> , 2019, 44, 62-75.	3.5	8
105	Associations Between Gut Microbiota and Alzheimer's Disease: Current Evidences and Future Therapeutic and Diagnostic Perspectives. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 25-31.	2.6	21
106	FA-97, a New Synthetic Caffeic Acid Phenethyl Ester Derivative, Protects against Oxidative Stress-Mediated Neuronal Cell Apoptosis and Scopolamine-Induced Cognitive Impairment by Activating Nrf2/HO-1 Signaling. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-21.	4.0	67
107	Transcranial Direct Current Stimulation Improves Cognitive Function in Mild to Moderate Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 170-178.	1.3	34
108	CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity. <i>Neuropharmacology</i> , 2019, 147, 4-10.	4.1	17
109	Interactions of Selective Serotonin Reuptake Inhibitors with β -Amyloid. <i>ACS Chemical Neuroscience</i> , 2019, 10, 226-234.	3.5	16
110	microRNA diagnostic panel for Alzheimer's disease and epigenetic trade-off between neurodegeneration and cancer. <i>Ageing Research Reviews</i> , 2019, 49, 125-143.	10.9	87
111	New approaches for the treatment of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 125-133.	2.2	111

#	ARTICLE	IF	CITATIONS
112	Phytochemical constituents from <i>Galanthus alpinus</i> Sosn. var. <i>alpinus</i> and their anticholinesterase activities. <i>South African Journal of Botany</i> , 2019, 121, 63-67.	2.5	2
113	Dose-response relationship between exercise and cognitive function in older adults with and without cognitive impairment: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0210036.	2.5	186
114	Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting. <i>Advanced Drug Delivery Reviews</i> , 2019, 140, 129-135.	13.7	20
115	A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. <i>ACS Chemical Neuroscience</i> , 2019, 10, 279-294.	3.5	18
116	Neuroprotective potential of <i>Myrciaria plinioides</i> D. Legrand extract in an in vitro human neuroblastoma model. <i>Inflammopharmacology</i> , 2020, 28, 737-748.	3.9	8
117	Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. <i>Neuropsychopharmacology</i> , 2020, 45, 104-120.	5.4	280
118	The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development. <i>New Genetics and Society</i> , 2020, 39, 101-126.	1.2	8
119	Neuron-glia interaction through Serotonin-BDNF-NGFR axis enables regenerative neurogenesis in Alzheimer's model of adult zebrafish brain. <i>PLoS Biology</i> , 2020, 18, e3000585.	5.6	73
120	The antidepressant drug; trazodone inhibits Tau amyloidogenesis: Prospects for prophylaxis and treatment of AD. <i>Archives of Biochemistry and Biophysics</i> , 2020, 679, 108218.	3.0	18
121	Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease. <i>Clinics in Laboratory Medicine</i> , 2020, 40, 289-303.	1.4	2
122	An Isoquinolinium Dual Inhibitor of Cholinesterases and Amyloid β Aggregation Mitigates Neuropathological Changes in a Triple-Transgenic Mouse Model of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3346-3357.	3.5	7
123	Association between Intake of Energy and Macronutrients and Memory Impairment Severity in US Older Adults, National Health and Nutrition Examination Survey 2011-2014. <i>Nutrients</i> , 2020, 12, 3559.	4.1	8
124	Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 144.	6.2	29
125	Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 43.	10.8	104
126	Network Simulations Reveal Molecular Signatures of Vulnerability to Age-Dependent Stress and Tau Accumulation. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 590045.	3.5	1
127	GSK3 β /ARC/Arg3.1 and GSK3 β /Wnt signaling axes trigger amyloid β accumulation and neuroinflammation in middle-aged Shugoshin 1 mice. <i>Aging Cell</i> , 2020, 19, e13221.	6.7	15
128	Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer's Disease. <i>Pharmaceuticals</i> , 2020, 13, 242.	3.8	29
129	Repositioning of Immunomodulators: A Ray of Hope for Alzheimer's Disease?. <i>Frontiers in Neuroscience</i> , 2020, 14, 614643.	2.8	16

#	ARTICLE	IF	CITATIONS
130	Noninvasive characterization of Alzheimer's disease by circulating, cell-free messenger RNA next-generation sequencing. <i>Science Advances</i> , 2020, 6, .	10.3	39
131	Peptide based drug delivery systems to the brain. <i>Nano Express</i> , 2020, 1, 012002.	2.4	22
132	Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1-infected patients. <i>Aids</i> , 2020, 34, 893-902.	2.2	11
133	Combination Drug Therapy for the Management of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3272.	4.1	110
134	White Matter Brain Network Research in Alzheimer's Disease Using Persistent Features. <i>Molecules</i> , 2020, 25, 2472.	3.8	11
135	On the horizon—the value and promise of the global pipeline of Alzheimer's disease therapeutics. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12009.	3.7	14
136	New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3765.	4.1	6
137	Pre-trained MRI-based Alzheimer's disease classification models to classify memory clinic patients. <i>NeuroImage: Clinical</i> , 2020, 27, 102303.	2.7	4
138	Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions. <i>Life Sciences</i> , 2020, 256, 117996.	4.3	129
139	Design, synthesis, molecular docking, biological evaluations and QSAR studies of novel dichloroacetate analogues as anticancer agent. <i>Journal of Molecular Structure</i> , 2020, 1221, 128689.	3.6	14
140	Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event-based model of disease progression. <i>Alzheimer's and Dementia</i> , 2020, 16, 965-973.	0.8	30
141	Pharmacogenetic studies in Alzheimer disease. <i>Neurologia (English Edition)</i> , 2022, 37, 287-303.	0.4	4
142	Effects of low- and high-intensity physical exercise on physical and cognitive function in older persons with dementia: a randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 28.	6.2	55
143	Olesoxime improves cerebral mitochondrial dysfunction and enhances A β levels in preclinical models of Alzheimer's disease. <i>Experimental Neurology</i> , 2020, 329, 113286.	4.1	10
144	NHANES 2011–2014 Reveals Cognition of US Older Adults may Benefit from Better Adaptation to the Mediterranean Diet. <i>Nutrients</i> , 2020, 12, 1929.	4.1	28
145	Protofibrils of Amyloid- β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 952.	4.1	41
146	Characterization of phenolic profile by LC-ESI-MS/MS and enzyme inhibitory activities of two wild edible garlic: <i>Allium nigrum</i> L. and <i>Allium subhirsutum</i> L. <i>Journal of Food Biochemistry</i> , 2020, 44, e13165.	2.9	27
148	Uncovering the Pharmacological Mechanism of Stemazole in the Treatment of Neurodegenerative Diseases Based on a Network Pharmacology Approach. <i>International Journal of Molecular Sciences</i> , 2020, 21, 427.	4.1	16

#	ARTICLE	IF	CITATIONS
149	Deep Eutectic Solvents as Effective Reaction Media for the Synthesis of 2-Hydroxyphenylbenzimidazole-Based Scaffolds en Route to Donepezil-Like Compounds. <i>Molecules</i> , 2020, 25, 574.	3.8	22
150	Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. <i>Biochemical Pharmacology</i> , 2020, 177, 113945.	4.4	62
151	Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2020, 1868, 140428.	2.3	91
152	Is Alzheimer's Disease a Liver Disease of the Brain?. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1-14.	2.6	58
153	Polymeric Nanoparticles for Nasal Drug Delivery to the Brain: Relevance to Alzheimer's Disease. <i>Advanced Therapeutics</i> , 2021, 4, 2000076.	3.2	61
154	(m)RVD-hemopressin (\hat{I}_{\pm}) and (m)VD-hemopressin (\hat{I}_{\pm}) improve the memory-impairing effect of scopolamine in novel object and object location recognition tasks in mice. <i>Peptides</i> , 2021, 136, 170442.	2.4	3
155	Cognitive assessment tools for mild cognitive impairment screening. <i>Journal of Neurology</i> , 2021, 268, 1615-1622.	3.6	77
156	Fractal motor activity regulation and sex differences in preclinical Alzheimer's disease pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12211.	2.4	12
157	Who funds Alzheimer's disease drug development?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12185.	3.7	7
158	The Pathogenesis Mechanism, Structure Properties, Potential Drugs and Therapeutic Nanoparticles against the Small Oligomers of Amyloid- β^2 . <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 151-167.	2.1	5
159	Repurposing ibuprofen-loaded microemulsion for the management of Alzheimer's disease: evidence of potential intranasal brain targeting. <i>Drug Delivery</i> , 2021, 28, 1188-1203.	5.7	12
160	Oxidative Stress and Antioxidant Strategies in Human Diseases. , 2021, , 1-26.		0
161	Modification of amyloid-beta peptide aggregation via photoactivation of strained Ru(polypyridyl) complexes. <i>Chemical Science</i> , 2021, 12, 7510-7520.	7.4	15
162	24(S)-Saringosterol Prevents Cognitive Decline in a Mouse Model for Alzheimer's Disease. <i>Marine Drugs</i> , 2021, 19, 190.	4.6	12
163	A Comprehensive Performance Analysis of Neurodegenerative diseases Incidence based on Epidemiological Study in the Female subjects over varied data. <i>Advances in Distributed Computing and Artificial Intelligence Journal</i> , 2021, 10, .	1.5	2
164	Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4972-4990.	6.4	63
165	Effects of Morning Blue-Green 500nm Light Therapy on Cognition and Biomarkers in Middle-Aged and Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment: Study Protocol for a Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1521-1536.	2.6	6
166	Beyond the average patient: how neuroimaging models can address heterogeneity in dementia. <i>Brain</i> , 2021, 144, 2946-2953.	7.6	46

#	ARTICLE	IF	CITATIONS
167	Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application. Journal of Alzheimer's Disease, 2021, 81, 19-32.	2.6	3
168	Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways. Current Neuropharmacology, 2021, 19, 885-895.	2.9	6
169	Efficacy of Jihwangeumja (Dihuang Yinzi) on cognitive function and activities of daily living in patients with Alzheimer disease. Medicine (United States), 2021, 100, e25592.	1.0	5
170	Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer's Disease. Applied Sciences (Switzerland), 2021, 11, 4305.	2.5	26
171	A Comparison of Connected Speech Tasks for Detecting Early Alzheimer's Disease and Mild Cognitive Impairment Using Natural Language Processing and Machine Learning. Frontiers in Computer Science, 2021, 3, .	2.8	20
172	Nutraceuticals-based therapeutic approach: recent advances to combat pathogenesis of Alzheimer's disease. Expert Review of Neurotherapeutics, 2021, 21, 625-642.	2.8	19
173	Aducanumab for Alzheimer's disease: An update. Neuroscience Research Notes, 2021, 4, 17-20.	0.8	3
174	Exercise mimetics: harnessing the therapeutic effects of physical activity. Nature Reviews Drug Discovery, 2021, 20, 862-879.	46.4	55
175	Sanweidoukou decoction, a Chinese herbal formula, ameliorates $\text{A}\beta$ -amyloid protein-induced neuronal insult via modulating MAPK/NF- κ B signaling pathways: Studies in vivo and in vitro. Journal of Ethnopharmacology, 2021, 273, 114002.	4.1	12
177	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
178	The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 2021, 16, 49.	10.8	43
179	Identification of Multi-Target Anti-AD Chemical Constituents From Traditional Chinese Medicine Formulae by Integrating Virtual Screening and In Vitro Validation. Frontiers in Pharmacology, 2021, 12, 709607.	3.5	7
180	Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Implications by Natural Products. Mediators of Inflammation, 2021, 2021, 1-21.	3.0	36
181	Whole-blood metabolomics of dementia patients reveal classes of disease-linked metabolites. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	51
182	Development of curcumin-based amyloid $\text{A}\beta$ aggregation inhibitors for Alzheimer's disease using the SAR matrix approach. Bioorganic and Medicinal Chemistry, 2021, 46, 116357.	3.0	6
183	Efficacy of preclinical pharmacological interventions against alterations of neuronal network oscillations in Alzheimer's disease: A systematic review. Experimental Neurology, 2021, 343, 113743.	4.1	7
184	Oxidative Stress and Beta Amyloid in Alzheimer's Disease. Which Comes First: The Chicken or the Egg?. Antioxidants, 2021, 10, 1479.	5.1	64
185	Intranasal route: The green corridor for Alzheimer's disease therapeutics. Journal of Drug Delivery Science and Technology, 2021, 66, 102791.	3.0	2

#	ARTICLE	IF	CITATIONS
186	Pathological mechanisms and therapeutic strategies for Alzheimer's disease. Neural Regeneration Research, 2022, 17, 543.	3.0	146
187	Quercetin. , 2021, , 109-115.		0
188	Temporal Dynamics of β -Amyloid Accumulation in Aging and Alzheimer Disease. Neurology, 2021, 96, e1347-e1357.	1.1	54
189	Neuroactive venom compounds obtained from Phlogiellus bundokalbo as potential leads for neurodegenerative diseases: insights on their acetylcholinesterase and beta-secretase inhibitory activities in vitro. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2021, 27, e20210009.	1.4	0
190	Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12107.	3.7	15
191	Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases. International Review of Neurobiology, 2020, 155, 203-234.	2.0	50
194	How non-drug interventions affect the quality of life of patients suffering from progressive cognitive decline and their main caregiver. Aging, 2020, 12, 10754-10771.	3.1	5
195	Alzheimer's disease with an early debut. Meditsinskiy Sovet, 2019, , 10-16.	0.5	3
196	Neuropeptides in Alzheimer's Disease: An Update. Current Alzheimer Research, 2019, 16, 544-558.	1.4	31
197	Genetic Variants and Oxidative Stress in Alzheimer's Disease. Current Alzheimer Research, 2020, 17, 208-223.	1.4	23
198	Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease. Current Neuropharmacology, 2018, 16, 758-768.	2.9	12
199	Recent Trends in the Management of Alzheimer's Disease: Current Therapeutic Options and Drug Repurposing Approaches. Current Neuropharmacology, 2020, 18, 868-882.	2.9	16
200	A Comprehensive Review of Alzheimer's Association with Related Proteins: Pathological Role and Therapeutic Significance. Current Neuropharmacology, 2020, 18, 674-695.	2.9	18
201	Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease. Experimental and Therapeutic Medicine, 2020, 20, 1789-1795.	1.8	12
202	Alzheimer's disease, neural stem cells and neurogenesis: cellular phase at single-cell level. Neural Regeneration Research, 2020, 15, 824.	3.0	29
203	Enzyme-digested Colla Corii Asini (E TM jiao) prevents hydrogen peroxide-induced cell death and accelerates amyloid beta clearance in neuronal-like PC12 cells. Neural Regeneration Research, 2020, 15, 2270.	3.0	16
204	Computer-Aided Multi-Target Management of Emergent Alzheimer's Disease. Bioinformation, 2018, 14, 167-180.	0.5	3
205	Quantitative description of publications (1986-2020) related to Alzheimer disease and oxidative stress: A bibliometric study. Journal of Cellular Neuroscience and Oxidative Stress, 2021, 13, 971-984.	0.2	1

#	ARTICLE	IF	CITATIONS
206	Salpyran: A Cu(II) Selective Chelator with Therapeutic Potential. Inorganic Chemistry, 2021, 60, 15310-15320.	4.0	3
207	Aggregation and structure of amyloid β -protein. Neurochemistry International, 2021, 151, 105208.	3.8	19
208	Que penser de l'approche m�dicamenteuse pr�ventive de la maladie d'Alzheimer ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 679-690.	0.0	0
209	Alzheimerio ligos gydymo metod� paie�jka: klinikini� tyrim� kryptys. Neurologijos Seminarai, 2018, 22, 21-30.	0.0	0
211	New strategies for diagnosis and treatment of Alzheimer's disease: monoclonal antibodies to beta-amyloid. Medical Alphabet, 2019, 1, 35-42.	0.2	4
212	Human Nervous System Disorders. Advances in Bioinformatics and Biomedical Engineering Book Series, 2019, , 468-528.	0.4	0
213	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. , 2019, , 1-119.		0
216	EFFECT OF PUMPKIN (CUCURBITA PEPO L.) AND MARIGOLD (TAGETES PATULA L.) EXTRACTS ON HIPPOCAMPAL MITOCHONDRIA FUNCTIONAL ACTIVITY WITHIN CONDITIONS OF EXPERIMENTAL ACUTE BRAIN HYPOMETABOLISM. Farmatsiya I Farmakologiya, 2019, 7, 198-207.	0.6	2
218	Effect of Autranellacongolensis on Lipid Profile of Rats' Brain with Experimentally Induced Alzheimer's Disease. Journal of Food Research, 2020, 9, 60.	0.3	1
219	Design, Synthesis and Acetylcholinesterase and Butylcholinesterase Inhibition Activity of Novel 1-(Alkyl)-3-(2-oxo-2H-chromenyloxy acetamido) methylpyridinium Salts. Letters in Organic Chemistry, 2020, 17, .	0.5	0
221	GC/MS Analysis of Alkaloids in Galanthus fosteri Baker and Determination of Its Anticholinesterase Activity. Turkish Journal of Pharmaceutical Sciences, 2020, 17, 36-42.	1.4	4
222	Evaluation of Available Cognitive Tools Used to Measure Mild Cognitive Decline: A Scoping Review. Nutrients, 2021, 13, 3974.	4.1	20
223	Mild Cognitive Impairment: Current Aspects of Diagnosis and Treatment. Neuroscience and Behavioral Physiology, 2021, 51, 1033-1039.	0.4	0
224	The Role and Mechanisms of Action of Catechins in Neurodegenerative Diseases. Journal of the American College of Nutrition, 2023, 42, 67-74.	1.8	4
225	The Neurocognitive Effects of Cannabis Across the Lifespan. Current Behavioral Neuroscience Reports, 2021, 8, 124-133.	1.3	3
226	Subtle mistakes in self-report surveys predict future transition to dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12252.	2.4	5
227	Electrophysiological resting state brain network and episodic memory in healthy aging adults. Neurolmage, 2022, 253, 118926.	4.2	4
228	Assessing and disclosing test results for 'mild cognitive impairment': the perspective of old age psychiatrists in Scotland. BMC Geriatrics, 2022, 22, 50.	2.7	5

#	ARTICLE	IF	CITATIONS
229	Detoxification of amyloid β fibrils by curcumin derivatives and their verification in a Drosophila Alzheimer's model. Chemical Communications, 2022, , .	4.1	10
230	A New Series of Aryloxyacetic Acids Endowed with Multi-Target Activity towards Peroxisome Proliferator-Activated Receptors (PPARs), Fatty Acid Amide Hydrolase (FAAH), and Acetylcholinesterase (AChE). Molecules, 2022, 27, 958.	3.8	7
231	DOTA: Deep Learning Optimal Transport Approach to Advance Drug Repositioning for Alzheimer's Disease. Biomolecules, 2022, 12, 196.	4.0	8
232	Synthesis, characterization, and biological evaluation of some novel Schiff bases as potential metabolic enzyme inhibitors. Archiv Der Pharmazie, 2022, 355, e2100430.	4.1	19
233	Pharmacokinetics and Pharmacodynamics of Key Components of a Standardized Centella asiatica Product in Cognitively Impaired Older Adults: A Phase 1, Double-Blind, Randomized Clinical Trial. Antioxidants, 2022, 11, 215.	5.1	10
234	Thymol protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson's disease via inhibiting oxidative stress. BMC Complementary Medicine and Therapies, 2022, 22, 40.	2.7	7
235	Nanomedical drug delivery for neurodegenerative disease. , 2022, , 67-79.		1
236	Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age. Biomolecules, 2022, 12, 371.	4.0	59
237	The Role of the Contract Research Organization in Alzheimer's Disease: The Vital Link in the Clinical Drug-Development Program. , 2022, , 309-318.		0
238	Neurofilament light chain in cerebrospinal fluid or blood as a biomarker for mild cognitive impairment. Medicine (United States), 2022, 101, e28932.	1.0	6
239	Institutional Review Boards and Oversight of Alzheimer's Disease Trials. , 2022, , 429-436.		0
240	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. Journal of Alzheimer's Disease, 2022, 86, 1399-1413.	2.6	15
241	Metabolomics profiling, biological activities, and molecular docking studies of elephant garlic (Allium ampeloprasum L.). Process Biochemistry, 2022, 116, 49-59.	3.7	7
242	Identification of potential lead compounds against BACE1 through in-silico screening of phytochemicals of Medhya rasayana plants for Alzheimer's disease management. Computers in Biology and Medicine, 2022, 145, 105422.	7.0	4
252	Inhibition of aluminum chloride-induced amyloid $A\beta$ peptide accumulation and brain neurodegeneration by flower decoction.. Iranian Journal of Basic Medical Sciences, 2021, 24, 1437-1445.	1.0	1
254	Selective Serotonin Reuptake Inhibitor-Treatment Does Not Show Beneficial Effects on Cognition or Amyloid Burden in Cognitively Impaired and Cognitively Normal Subjects. Frontiers in Aging Neuroscience, 0, 14, .	3.4	4
255	Overview of therapeutic targets in management of dementia. Biomedicine and Pharmacotherapy, 2022, 152, 113168.	5.6	15
256	The role of mixed B vitamin intakes on cognitive performance: Modeling, genes and miRNAs involved. Journal of Psychiatric Research, 2022, 152, 38-56.	3.1	17

#	ARTICLE	IF	CITATIONS
259	Amylin and Secretases in the Pathology and Treatment of Alzheimer's Disease. <i>Biomolecules</i> , 2022, 12, 996.	4.0	5
260	PHOSPHODIESTERASE (PDE) INHIBITORS IN ALZHEIMER'S DISEASE: ROLE AND CURRENT STATUS. <i>Indian Drugs</i> , 2022, 59, 7-16.	0.1	0
261	Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114578.	5.5	19
262	Discovery and validation of dominantly inherited Alzheimer's disease mutations in populations from Latin America. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	2
263	Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	16
264	Binding Models of A β 42 Peptide with Membranes Explored by Molecular Simulations. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 6482-6493.	5.4	6
265	Analysis of ROQUIN, Tristetraprolin (TTP), and BDNF/miR-16/TTP regulatory axis in late onset Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	7
267	Anti-Inflammatory Activity of 4-(4-(Heptyloxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one via Repression of MAPK/NF- κ B Signaling Pathways in β 2-Amyloid-Induced Alzheimer's Disease Models. <i>Molecules</i> , 2022, 27, 5035.	3.8	6
268	The promising role of natural products in Alzheimer's disease. <i>Brain Disorders</i> , 2022, 7, 100049.	1.7	10
270	Effect of cx-DHED on Abnormal Glucose Transporter Expression Induced by AD Pathologies in the 5xFAD Mouse Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10602.	4.1	3
271	Neuroinflammation and Oxidative Stress in Alzheimer's Disease; Can Nutraceuticals and Functional Foods Come to the Rescue?. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2021, 21, 75-89.	1.1	4
272	Role of 3D Printing in the Development of Biodegradable Implants for Central Nervous System Drug Delivery. <i>Molecular Pharmaceutics</i> , 2022, 19, 4411-4427.	4.6	8
273	The effects of aerobic exercise and transcranial direct current stimulation on cognitive function in older adults with and without cognitive impairment: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2022, 81, 101738.	10.9	10
274	Pharmacological evaluation of newly synthesized benzimidazole derivative for anti-Alzheimer potential. <i>International Journal of Neuroscience</i> , 0, , 1-17.	1.6	1
275	Dysphagia in Alzheimer's disease. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2022, 14, 83-89.	1.2	0
276	Biological and therapeutic role of LSD1 in Alzheimer's diseases. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
277	The Link between Oxidative Stress, Mitochondrial Dysfunction and Neuroinflammation in the Pathophysiology of Alzheimer's Disease: Therapeutic Implications and Future Perspectives. <i>Antioxidants</i> , 2022, 11, 2167.	5.1	17
278	Immunosenescence and Aging: Neuroinflammation Is a Prominent Feature of Alzheimer's Disease and Is a Likely Contributor to Neurodegenerative Disease Pathogenesis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1817.	2.5	7

#	ARTICLE	IF	CITATIONS
279	Liposome: A potential drug delivery vector to treat dementia. , 2023, , 149-168.		0
280	Hydroxycoumarins and some Flavonoids from Pistacia atlantica Desf. as Multi-targets Inhibitors for Alzheimer's Disease: Molecular Docking and ADMET Studies. Current Computer-Aided Drug Design, 2023, 19, 176-191.	1.2	1
281	Green Tea Catechins Attenuate Neurodegenerative Diseases and Cognitive Deficits. Molecules, 2022, 27, 7604.	3.8	19
282	Holothuria scabra extracts confer neuroprotective effect in C.Âelegans model of Alzheimer's disease by attenuating amyloid-Î² aggregation and toxicity. Journal of Traditional and Complementary Medicine, 2023, 13, 93-104.	2.7	4
283	Focus on Alzheimer's Disease: The Role of Fibroblast Growth Factor 21 and Autophagy. Neuroscience, 2023, 511, 13-28.	2.3	2
284	A Review of CRISPR Cas9 for Alzheimer's Disease: Treatment Strategies and Could target APOE e4, APP, and PSEN-1 Gene using CRISPR cas9 Prevent the Patient from Alzheimer's Disease?. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 745-757.	0.2	1
285	Suppression of Selective Voltage-Gated Calcium Channels Alleviates Neuronal Degeneration and Dysfunction through Glutathione S-Transferase-Mediated Oxidative Stress Resistance in a Caenorhabditis elegans Model of Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-19.	4.0	3
286	Alzheimer's disease and COVID-19. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 89-97.	1.2	0
287	Disclosure of Genetic Risk Factors for Alzheimer's Disease to Cognitively Healthy Individualsâ€”From Current Practice towards a Personalised Medicine Scenario. Biomedicines, 2022, 10, 3177.	3.2	8
288	Network organization of resting-state cerebral hemodynamics and their aliasing contributions measured by functional near-infrared spectroscopy. Journal of Neural Engineering, 0, , .	3.5	0
289	Screening for Mild Cognitive Impairment Using a Machine Learning Classifier and the Remote Speech Biomarker for Cognition: Evidence from Two Clinically Relevant Cohorts. Journal of Alzheimer's Disease, 2022, , 1-7.	2.6	3
290	Flavonoid-enrich extract of Atranelia congolensis (Sapotaceae) protects against aluminium chloride-mediated Alzheimer's disease-like oxidative stress in rat through the antioxidant properties. Metabolic Brain Disease, 0, , .	2.9	0
291	The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators. Journal of Alzheimer's Disease, 2023, , 1-12.	2.6	2
294	Synthesis of N-((tert-Butylamino)â€”2-oxoethyl)-2,2-dichloro-N-aryl(alkyl)acetamides as Anticancer Agents: Molecular Modeling and Biological Evaluations. ChemistrySelect, 2023, 8, .	1.5	1
297	Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases. Disease-a-Month, 2023, 69, 101547.	1.1	4
298	Glutathione depletion results in S-nitrosylation of protein disulfide isomerase in neuroblastoma cells. Life Sciences, 2023, 316, 121442.	4.3	1
299	Spatial and Temporal Protein Modules Signatures Associated with Alzheimer Disease in 3xTg-AD Mice Are Restored by Early Ubiquinol Supplementation. Antioxidants, 2023, 12, 747.	5.1	2
300	Design of a Non-Interventional Study to Assess Neurologists's Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease. Neurology and Therapy, 2023, 12, 995-1006.	3.2	1

#	ARTICLE	IF	CITATIONS
301	Alterations of Spatial Memory and Gut Microbiota Composition in Alzheimer's Disease Triple-Transgenic Mice at 3, 6, and 9 Months of Age. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2023, 38, 153331752311741.	1.9	1
302	Guizhi Fuling capsule relieves memory deficits by inhibition of microglial neuroinflammation through blocking JAK2/STAT3 pathway in presenilin1/2 conditional double knockout mice. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
303	Gut-brain connections in neurodegenerative disease: immunotherapeutic targeting of Bin1 in inflammatory bowel disease and Alzheimer's disease. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
304	Comparative neurogenetics of dog behavior complements efforts towards human neuropsychiatric genetics. <i>Human Genetics</i> , 2023, 142, 1231-1246.	3.8	1
305	Evaluation of Efficacy and Safety Using Low Dose Radiation Therapy with Alzheimer's Disease: A Protocol for Multicenter Phase II Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2023, 95, 1263-1272.	2.6	2
306	Current Advances in Mitochondrial Targeted Interventions in Alzheimer's Disease. <i>Biomedicines</i> , 2023, 11, 2331.	3.2	3
307	Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development. <i>Cellular and Molecular Neurobiology</i> , 0, , .	3.3	3
308	Current evidence for J147 as a potential therapeutic agent in nervous system disease: a narrative review. <i>BMC Neurology</i> , 2023, 23, .	1.8	2
309	Using artificial intelligence to learn optimal regimen plan for Alzheimer's disease. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2023, 30, 1645-1656.	4.4	2
310	Antioxidative and neuroprotective potential of <i>Acorus calamus</i> linn. and <i>Cordia dichotoma</i> G. Forst. In Alzheimer's type dementia in rodent. <i>Brain Research</i> , 2024, 1822, 148616.	2.2	1
311	±S1-Casein-Loaded Proteo-liposomes as Potential Inhibitors in Amyloid Fibrillogenesis: In Vivo Effects on a C. elegans Model of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 0, , .	3.5	0
312	Recent advancement in therapeutic strategies for Alzheimer's disease: Insights from clinical trials. <i>Ageing Research Reviews</i> , 2023, 92, 102113.	10.9	2
313	Calciopathies and Neuropsychiatric Disorders: Physiological and Genetic Aspects. <i>Neuroscience and Behavioral Physiology</i> , 2023, 53, 1269-1282.	0.4	0
314	Betula pendula Leaf Extract Targets the Interplay between Brain Oxidative Stress, Inflammation, and NFκB Pathways in Amyloid Aβ ²¹⁻⁴² -Treated Rats. <i>Antioxidants</i> , 2023, 12, 2110.	5.1	0
315	Effect of Human Milk Oligosaccharides on Learning and Memory in Mice with Alzheimer's Disease. <i>Journal of Agricultural and Food Chemistry</i> , 0, , .	5.2	0
316	Hyperbaric oxygen alleviates selective domains of cognitive and motor deficits in female 5xFAD mice. <i>GeroScience</i> , 0, , .	4.6	0
317	The Structural Basis of DL0410, a Novel Multi-Target Candidate Drug for the Treatment of Alzheimer's Disease. <i>Crystals</i> , 2024, 14, 59.	2.2	0
318	Pharmacokinetics and pharmacodynamics of various novel formulations targeting Alzheimer's disease. , 2024, , 391-402.		1

#	ARTICLE	IF	CITATIONS
319	Natural products as potential modulators of pro-inflammatory cytokines signalling in Alzheimer's disease. , 2024, 5, 100048.		0
320	CoQ10 and Mitochondrial Dysfunction in Alzheimer’s Disease. Antioxidants, 2024, 13, 191.	5.1	0
321	A Longitudinal Study on Cognitive Training for Cognitively Preserved Adults in Liguria, Italy. Healthcare (Switzerland), 2024, 12, 393.	2.0	0
323	Unraveling brain diseases: The promise of brain-on-a-chip models. Journal of Neuroscience Methods, 2024, 405, 110105.	2.5	0